FDA Adverse Event Injury Summary report: N

IRR FCP BAY BIP 8 3/4 1.0

MDR report key: 1131383 · Received August 12, 2008

Report

Report Number
1226348-2008-00221
Event Type
Injury
Date Received
August 12, 2008
Date of Event
June 13, 2008
Report Date
July 22, 2008
Manufacturer
CODMAN & SHURTLEFF, INC.
Product Code
GEI
Removal / Correction Number
NA
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
RISK MANAGER

Narratives

Additional Manufacturer Narrative · 1

IT HAS BEEN COMMUNICATED THAT THE DEVICE IS NOT AVAILABLE FOR EVAL. WITHOUT THE DEVICE, IT IS NOT POSSIBLE FOR CODMAN TO CONDUCT A PROPER INVESTIGATION. SINCE A LOT NUMBER HAS BEEN PROVIDED, A REVIEW OF THE MFG RECORDS HAVE BEEN REVIEWED AND THEY REVEALED THAT THE DEVICE CONFORMED TO ALL MFG AND QUAL TESTING/INSPECTION SPECIFICATIONS PRIOR TO BEING RELEASED TO STOCK. IF AT SOME POINT THE DEVICE IS RETURNED FOR EVAL THIS COMPLAINT WILL BE RE-OPENED AND INVESTIGATED. BASED ON THIS EVAL NO FURTHER ACTION IS REQUIRED. TRENDS WILL BE MONITORED FOR THIS AND SIMILAR COMPLAINTS. AT THE PRESENT TIME, THIS COMPLAINT IS CLOSED. ADDITIONALLY, THE USE OF NON-INSULATED BIPOLAR FORCEPS IN CONFINED SPACES (E.G. TONSILLECTOMY) MAY RESULT IN UNINTENDED CONTACT WITH AND POSSIBLE INJURY TO NON-TARGET TISSUE DURING THE APPLICATION OF POWER TO THE FORCEPS. THE USE OF INSULTED FORCEPS IS RECOMMENDED FOR SUCH PROCEDURES. IT SHOULD ALSO BE MENTIONED THAT ACCORDING TO THE DEVICE LOT CODE, IT APPEARS THAT THIS DEVICE IS 17 YRS OLD.

Description of Event or Problem · 1

PT UNDERWENT SURGERY FOR CONTROL OF OROPHARYNGEAL BLEEDING POST TONSILLECTOMY USING BIPOLAR UNISULATED FORCEPS. AFTER SURGERY, IT WAS NOTED THAT APPROX 1/2 CM WHITE WOUND WAS NOTED AT THE RIGHT ORAL COMMISSURE. PT WAS SENT HOME 2 DAYS LATER WITH INSTRUCTIONS TO INCLUDE FOLLOW UP CARE FOR WOUND. THE DEVICE IS NOT AVAILABLE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 IRR FCP BAY BIP 8 3/4 1.0 ELECTROSURGICAL CUTTING AND COAGULATION DEVICE GEI CODMAN & SHURTLEFF, INC. NA 9106N

Patients

Seq Age Sex Outcome Treatment
1 7 YR